Literature DB >> 22275185

The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Peter T Yu1, Michele Babicky, Dawn Jaquish, Randy French, Karly Marayuma, Evangeline Mose, Sherry Niessen, Heather Hoover, David Shields, David Cheresh, Benjamin F Cravatt, Andrew M Lowy.   

Abstract

The recepteur d'origine nantais (RON) receptor tyrosine kinase is overexpressed and stimulates invasive growth in pancreatic cancer cells, yet the mechanisms that underlie RON-mediated phenotypes remain poorly characterized. To better understand RON function in pancreatic cancer cells, we sought to identify novel RON interactants using multidimensional protein identification analysis. These studies revealed plectin, a large protein of the spectrin superfamily, to be a novel RON interactant. Plectin is a multifunctional protein that complexes with integrin-β4 (ITGB4) to form hemidesmosomes, serves as a scaffolding platform crucial to the function of numerous protein signaling pathways and was recently described as an overexpressed protein in pancreatic cancer (Bausch D et al., Clin Cancer Res 2010; Kelly et al., PLoS Med 2008;5:e85). In this study, we demonstrate that on exposure to its ligand, macrophage-stimulating protein, RON binds to plectin and ITGB4, which results in disruption of the plectin-ITGB4 interaction and enhanced cell migration, a phenotype that can be recapitulated by small hairpin ribosomal nucleic acid (shRNA)-mediated suppression of plectin expression. We demonstrate that disruption of plectin-ITGB4 is dependent on RON and phosphoinositide-3 (PI3) kinase, but not mitogen-activated protein kinase (MEK), activity. Thus, in pancreatic cancer cells, plectin and ITGB4 form hemidesmosomes which serve to anchor cells to the extracellular matrix (ECM) and restrain migration. The current study defines a novel interaction between RON and plectin, provides new insight into RON-mediated migration and further supports efforts to target RON kinase activity in pancreatic cancer.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275185      PMCID: PMC3424378          DOI: 10.1002/ijc.27447

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Role of binding of plectin to the integrin beta4 subunit in the assembly of hemidesmosomes.

Authors:  J Koster; S van Wilpe; I Kuikman; S H M Litjens; A Sonnenberg
Journal:  Mol Biol Cell       Date:  2003-12-10       Impact factor: 4.138

Review 2.  Current insights into the formation and breakdown of hemidesmosomes.

Authors:  Sandy H M Litjens; José M de Pereda; Arnoud Sonnenberg
Journal:  Trends Cell Biol       Date:  2006-06-06       Impact factor: 20.808

3.  Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

Authors:  Jennifer M O'Toole; Karen E Rabenau; Kerri Burns; Dan Lu; Venkat Mangalampalli; Paul Balderes; Nicole Covino; Rajiv Bassi; Marie Prewett; Kimberly J Gottfredsen; Megan N Thobe; Yuan Cheng; Yiwen Li; Daniel J Hicklin; Zhenping Zhu; Susan E Waltz; Michael J Hayman; Dale L Ludwig; Daniel S Pereira
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

4.  Plectin scaffolds recruit energy-controlling AMP-activated protein kinase (AMPK) in differentiated myofibres.

Authors:  Martin Gregor; Aniko Zeöld; Susanne Oehler; Kerstin Andrä Marobela; Peter Fuchs; Günter Weigel; D Graham Hardie; Gerhard Wiche
Journal:  J Cell Sci       Date:  2006-04-11       Impact factor: 5.285

5.  Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.

Authors:  E Ramsay Camp; Anthony Yang; Mike J Gray; Fan Fan; Stanley R Hamilton; Douglas B Evans; Andrea T Hooper; Daniel S Pereira; Daniel J Hicklin; Lee M Ellis
Journal:  Cancer       Date:  2007-03-15       Impact factor: 6.860

6.  In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mouse.

Authors:  M P Vezeridis; G N Tzanakakis; P A Meitner; C M Doremus; L M Tibbetts; P Calabresi
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

Review 7.  Oncogenic signaling pathways activated by RON receptor tyrosine kinase.

Authors:  Alla Danilkovitch-Miagkova
Journal:  Curr Cancer Drug Targets       Date:  2003-02       Impact factor: 3.428

8.  The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration.

Authors:  Massimo M Santoro; Giovanni Gaudino; Pier Carlo Marchisio
Journal:  Dev Cell       Date:  2003-08       Impact factor: 12.270

Review 9.  Plakins in development and disease.

Authors:  Arnoud Sonnenberg; Ronald K H Liem
Journal:  Exp Cell Res       Date:  2007-04-19       Impact factor: 3.905

10.  Plectin-RACK1 (receptor for activated C kinase 1) scaffolding: a novel mechanism to regulate protein kinase C activity.

Authors:  Selma Osmanagic-Myers; Gerhard Wiche
Journal:  J Biol Chem       Date:  2004-02-14       Impact factor: 5.157

View more
  26 in total

Review 1.  Clinical significance of the integrin α6β4 in human malignancies.

Authors:  Rachel L Stewart; Kathleen L O'Connor
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

Review 2.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 3.  Plakins, a versatile family of cytolinkers: roles in skin integrity and in human diseases.

Authors:  Jamal-Eddine Bouameur; Bertrand Favre; Luca Borradori
Journal:  J Invest Dermatol       Date:  2013-12-19       Impact factor: 8.551

4.  Identification of a RON tyrosine kinase receptor binding peptide using phage display technique and computational modeling of its binding mode.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Mol Model       Date:  2017-08-19       Impact factor: 1.810

Review 5.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 6.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

7.  Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.

Authors:  Hang-Ping Yao; Liang Feng; Jian-Wei Zhou; Rui-Wen Zhang; Ming-Hai Wang
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

8.  Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGΒ4-PDCD4) as predictor of metastatic tumor potential.

Authors:  Angelo Ferraro; Christos K Kontos; Themis Boni; Ioannis Bantounas; Dimitra Siakouli; Vivian Kosmidou; Margarita Vlassi; Yannis Spyridakis; Iraklis Tsipras; George Zografos; Alexander Pintzas
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

9.  Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.

Authors:  Kinlin L Chao; Natalia V Gorlatova; Edward Eisenstein; Osnat Herzberg
Journal:  J Biol Chem       Date:  2014-09-05       Impact factor: 5.157

10.  Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer.

Authors:  Soo J Shin; Jeffrey A Smith; Günther A Rezniczek; Sheng Pan; Ru Chen; Teresa A Brentnall; Gerhard Wiche; Kimberly A Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.